Dymista generic
Dymista is an anti-allergic drug owned by Mylan Specialty Lp. The drug has Azelastine Hydrochloride and Fluticasone Propionate as its active ingredients. Dymista was first authorized for market use on May 1, 2012.
When will Dymista generic be available?
The generic version of Dymista could potentially be released after August 24, 2026. This date corresponds to the expiry of the last patent (US8168620*PED) held by the drug. The generic release date is determined by the last patent's expiry and not necessarily the first market authorization date.
Dymista uses
Dymista can be used for the treatment of seasonal allergic rhinitis, allergic rhinitis, including seasonal allergic rhinitis, and relief of symptoms associated with seasonal allergic rhinitis. Its active ingredients, Azelastine Hydrochloride and Fluticasone Propionate, help in effectively managing these conditions.
Dymista patent expiration
Dymista has a total of 7 patents, 4 of which are already expired. The remaining active patents expire between 2023 and 2026, with the last one (US8168620*PED) set for expiry on August 24, 2026. As a result, the Dymista generic could possibly be released after this date. Below are the details of the patent: